A Brief History and Future Prospects of CEST MRI in Clinical Non-Brain Tumor Imaging

Tianxin Gao 1, Chuyue Zou 1, Yifan Li 2, Zhenqi Jiang 1, Xiaoying Tang 1,* and Xiaolei Song 2,*

1 School of Life Science, Institute of Engineering Medicine, Beijing Institute of Technology, Beijing 100081, China; gtx@bit.edu.cn (T.G.); zou15211137@163.com (C.Z.); 7520200073@bit.edu.cn (Z.J.)
2 Center for Biomedical Imaging Research, School of Medicine, Tsinghua University, Beijing 100084, China; yifan.li@pku.edu.cn
* Correspondence: xiaoying@bit.edu.cn (X.T.); songxl@tsinghua.edu.cn (X.S.)

Abstract: Chemical exchange saturation transfer (CEST) MRI is a promising molecular imaging tool which allows the specific detection of metabolites that contain exchangeable amide, amine, and hydroxyl protons. Decades of development have progressed CEST imaging from an initial concept to a clinical imaging tool that is used to assess tumor metabolism. The first translation efforts involved brain imaging, but this has now progressed to imaging other body tissues. In this review, we summarize studies using CEST MRI to image a range of tumor types, including breast cancer, pelvic tumors, digestive tumors, and lung cancer. Approximately two thirds of the published studies involved breast or pelvic tumors which are sites that are less affected by body motion. Most studies conclude that CEST shows good potential for the differentiation of malignant from benign lesions with a number of reports now extending to compare different histological classifications along with the effects of anti-cancer treatments. Despite CEST being a unique 'label-free' approach with a higher sensitivity than MR spectroscopy, there are still some obstacles for implementing its clinical use. Future research is now focused on overcoming these challenges. Vigorous ongoing development and further clinical trials are expected to see CEST technology become more widely implemented as a mainstream imaging technology.

Keywords: chemical exchange saturation transfer; body tumor; clinical scanner; amide proton transfer

1. Introduction

Magnetization transfer (MT) technology in magnetic resonance imaging (MRI), referring to the transfer of longitudinal magnetization between two proton groups, was first proposed by Wolff and Balaban et al. in 1989 [1]. Conventional MT is the transfer of magnetization between water and semisolid macromolecules. In 1998, Guivel-Scharen observed the asymmetry of the Z-spectrum near the resonance frequency of water when studying the MT phenomenon of small molecule solutions [2]. Later, in the year 2000, by combining magnetization transfer and chemical exchange, Wolff and Balaban first obtained the MR contrast images of several small molecules and named this novel molecular imaging technique chemical exchange saturation transfer (CEST) [3].

This imaging technology has attracted a number of preclinical and clinical research studies [4,5], becoming a promising molecular imaging tool that is available in the clinic [6,7]. Particularly, CEST imaging has been explored in assessing tumor metabolism, pH microenvironment, and histological types [4–6]. Like other MR techniques, CEST has been intensively investigated for characterizing brain tumors, with several dedicated reviews [6,8]. CEST has also been widely studied in non-brain tumors, especially in recent years with the progress in CEST acquisition sequences and post-processing methods. Compared with brain tumor imaging, CEST imaging of body tumors faces several common technical challenges including fat interference, motion artifacts, the $B_0/B_1$ inhomogeneity, and the power restrictions that are required for a larger field of view than the brain. Compared
with the brain, body imaging also has other unique properties, including the absence of the blood-brain-barrier and more heterogeneous tissue composition. To address the current status and future prospects of body CEST imaging, this review provides a survey of the application of CEST for imaging various tumors throughout the body, in particular methods that are performed as part of clinical imaging applications.

The literature search was performed through the electronic databases of Web of Science Core Collection for original studies that were published in English up to 30 September 2021. The keywords of the included studies covered three domains: 1: “chemical exchange saturation transfer” or “amide proton transfer”, 2: “tumor” or “cancer”, 3: “clinical” or “patient”. The exclusion criterion were the studies that related to “brain” or “glioma”. The complete search strategy was ((TS = (“Chemical Exchange Saturation Transfer” *)) OR (TS = (“Amide Proton Transfer”*)) AND ((TS = (tumor*)) OR (TS = (cancer*))) AND (TS = (clinical*) OR (TS = (patient*)) NOT (TS = (brain OR glioma*)). Of the 92 studies that were found, 65 were non-review articles, in which 44 focused on the clinical usage of CEST with human subjects. The tumor types that were reviewed here and the relevant references that were identified are listed in Figure 1.

| Cancer type     | Num. of studies | Num. of 7 T studies |
|-----------------|-----------------|---------------------|
| 1: Breast cancer| 12              | 5                   |
| 2: Cervix uteri*| 4               | -                   |
| 3: Corpus uteri*| 5               | -                   |
| 4: Ovary*       | 1               | -                   |
| 5: Prostate**   | 5               | -                   |
| 6: Rectum       | 5               | -                   |
| 7: Liver        | 3               | -                   |
| 8: Salivary gland| 5              | -                   |
| 9: Lung         | 3               | -                   |
| Total           | 43              | 5                   |

* female only, ** male only

Figure 1. Scope of the review, and an overview summary for the studies that were included. (a) Cancer types and the corresponding num. of studies included in the review, with 5 breast cancer studies performed on 7T MR scanners, and the rest performed on 3T scanners; (b) Studies’ distribution by publication year.

2. Principle of CEST

2.1. Basic Theory

CEST relies on the frequency-specific saturation of exchangeable protons on the detection molecules, with the saturated protons later transferred to surrounding water through multiple chemical exchange processes. To mathematically describe the CEST signal, Zhou et al. in 2004 [9] proposed a dual-pool model with exchange items, including a water pool and a solute pool. By selectively applying a radio-frequency (RF) saturation pulse at the resonance frequency of the exchangeable protons in the solute pool, the saturated solute protons transfer to the surrounding water pool through chemical exchange, resulting in decreases in the magnetic resonance signal of water [10]. As shown in Figure 2, the signal will decrease until a dynamic equilibrium of the chemical exchange is reached. By measuring the changes in water molecule signals, information about the solute molecules of interest, as well as the microenvironment, can be indirectly obtained. As the saturation and exchange process continually repeats, the reduction of water molecule signals is much greater than the signal intensity of the solute itself, making the minimal detectable concentrations as low as micromolar levels [11].
To achieve effective saturation transfer, two conditions are necessary. First, the resonant difference between the two exchanging proton pools is greater than the forward (from solute to water) exchange rate (\(\Delta \omega > k_{sw}\)), so that an effective exchange can be achieved. Second, the forward exchange rate is greater than the longitudinal relaxation rate of the protons of the solute pool (\(k_{sw} > R_{ls}\)), ensuring sufficient time for the exchange before complete relaxation [12].

Hydrogen protons in different chemical groups have different resonance frequencies due to their chemical environment, the offset of which from the resonance frequency of the hydrogen protons in free water (\(\omega_0\)) is an important characteristic, denoted as \(\Delta \omega\) (which is usually expressed in parts per million (ppm) of \(\omega_0\)), so that it keeps constant under different static magnetic fields (\(B_0\)). For example, amide protons resonate at 3.5 ppm from water. The normalized curve of the water signal along with the frequency offsets of the saturation pulses, namely a Z-spectrum, will display a ‘dip’ at \(\Delta \omega\), owing to the saturated signal that is transferred from the on-resonance proton groups to the water [13].

2.2. CEST Quantification

Compared with the intensity of unsaturated signals, signal reductions at certain frequency offsets derive not only from CEST, but also from the direct saturation (DS) of water, and moreover, from the MT effect of semisolid macromolecules during in vivo imaging. DS is symmetrical with respect to the resonance frequency of water, and the majority of MT is also symmetrical. Thus, the symmetrical effects can be removed by taking the difference between signal intensities at two opposite frequency offsets. This approach describes the idea of asymmetric analysis, a commonly used quantification approach that was proposed by Guivel et al. [2]. The measurement index is expressed as:

\[
\text{MTR}_{\text{asym}} = \frac{S(-\Delta \omega)-S(\Delta \omega)}{S_0}
\]

where \(S_0\) refers to the water signal intensity that is obtained when no pre-saturation pulse is applied, \(S(\Delta \omega)\) and \(S(-\Delta \omega)\) refer to the signal intensities that are obtained after applying pre-saturation pulses at \(\Delta \omega\) and \(-\Delta \omega\), respectively [13,14]. However, MTR_{asym} is unable to separate the CEST signals that are resonating down-field of water (\(\Delta \omega\) between 1−3.5 ppm), from the nuclear Overhauser effect (NOE) that is resonating up-field of water (\(\Delta \omega\) between −1.6 to −4 ppm) (see details in 2.3.4).

Another prevailing method of separating pure CEST signals is to subtract the experimental from the reference values that are free from CEST at a certain frequency offset (i.e., \(\text{MTR} = Z_{\text{ref}} - Z_{\text{exp}}\)). The latter can be estimated by different algorithms, including multi-pool Lorentzian fitting [15,16], Lorentzian difference (LD) [17], voxel-wise optimiza-
tion of pseudo Voigt profile (VOPVP) [18], the extrapolated semisolid MT model reference (EMR) approach [19], the three-offset method [20], and the multi-pool Bloch-McConnell fitting [21].

Based on similar estimation approaches of reference Z-spectra, inverse Z-spectrum analysis has been also used in some studies [22], according to which the size of the CEST effect is expressed as \( MTR_{\text{Rex}} = \frac{1}{Z_{\text{exp}}} - \frac{1}{Z_{\text{ref}}} \). Furthermore, to eliminate the influence of \( T_1 \) relaxation on the calculation of \( MTR_{\text{Rex}} \), the apparent exchange-dependent relaxation (AREX) was proposed and denoted as \( \text{AREX} = \frac{MTR_{\text{Rex}}}{T_{1w}} \), where the subscript \( w \) represents free water.

From the magnitude, width, and the frequency offsets of the CEST spectral peaks, as well as the signal dependence on the saturation length and power, information regarding the exchangeable protons on the solutes can be obtained [14]. Specifically, the solute concentrations and the microenvironmental pH could be sensed by means of clever designs and algorithms [23,24].

2.3. CEST Effects from Different Proton Groups

CEST effects can be classified into several categories according to the resonance frequencies of the exchangeable protons on the endogenous metabolites that include amide groups (-(CO)NH), amine groups (-NH\(_2\), and hydroxyl groups (-OH).

2.3.1. Imaging of Amide Protons

CEST can detect amide protons (-(CO)NH), resonating 3.5 ppm from water) on endogenous proteins and peptides, with the underlying phenomenon called amide proton transfer (APT) [25]. The first contrast images that were obtained of proteins and peptides using CEST technology were reported in 2003 by Zhou et al., achieving the detection of in vivo pH changes in an ischemic rat brain [25]. APT imaging was later used to achieve brain tumor imaging in rats, and thereafter in 2008, brain tumor imaging of human patients [26,27]. Compared with the amine and hydroxyl protons, amide protons resonate further to water protons and also exchange slower. Therefore, APT detection is less affected by field inhomogeneity and does not require high saturation \( B_1 \) as it does for the detection of the faster exchanged amines and hydroxyls.

\( MTR_{\text{asym}}(3.5 \text{ ppm}) \) is the most widely used metric for APT, which has demonstrated correlations with histological grade in brain tumors and could differentiate tumor recurrence from radiation necrosis [6,8,28]. However, \( MTR_{\text{asym}}(3.5 \text{ ppm}) \) includes multiple saturation-transfer effects from amide protons (3.5 ppm), aliphatic protons (3.5 ppm), and semisolid macromolecules and is, therefore, termed an APT-weighted (APTw) image. Nevertheless, the underlining mechanism of increased APTw signals in malignant tumors remains unclear, but proteomics analyses suggest an association with the abundance of certain metabolic proteins that are found in tumor tissues that are showing abnormal proliferation.

2.3.2. Imaging of Amine Protons

The amine (-NH\(_2\)) proton exhibits a peak frequency offset of ~3 ppm from water, but with a faster exchange rate than amide groups [29]. Amine contrast images were obtained either by the CEST technique with a high \( B_1 (>2 \mu T) \) or by another imaging sequence called spin-lock [29]. The endogenous contrast was assigned to the amine groups on proteins and peptides. The amine signal values (\( MTR_{\text{asym}} \)) at 3 ppm were found to differentiate between two major genotypes of gliomas, namely those that were expressing wild-type and mutant forms of isocitrate dehydrogenase 1 (IDH1). Additionally, the endogenous amine signals were believed to also be derived from the small molecule, glutamate, which is a common excitatory neurotransmitter in the central nervous system and also an important cell metabolite [30]. Cai et al. first used chemical exchange saturation transfer technology to image glutamate in vivo (GluCEST), with the altered glutamate content in lesions validated by MRS [30].
There is also a specific amine proton resonating ~2 ppm from water called guanidine amine. Creatine (Cr) and phosphor creatine (pCr) contain guanidine amine and amine groups, which can be detected by CEST. Potentially CrCEST and pCrCEST can provide assessments of tissue energy metabolism [31]. Using animal models of gliomas with different aggressiveness, CrCEST signals were found to be reduced within the tumor region, with highly aggressive tumors exhibiting more significant signal decreases [4]. The altered creatine concentration was explained by the decreased creatine kinase activity that was associated with increases in the degree of the tumor malignancy [32].

2.3.3. CEST Imaging of Hydroxyl Protons

Exchangeable hydroxyl protons are rich in glycan-containing endogenous molecules, including glycosaminoglycan (GAG) [33], glycogen [34,35], and glycoproteins [36], as well as glucose which is often used as an exogenous contrast agent.

Glycosaminoglycan (GAG), an important component of cartilage tissue, contains one \(-\text{NH}\) group and three \(-\text{OH}\) groups in each unit that can be detected by CEST. The GAGCEST technique was developed by Ling et al. [37] for mapping GAG content in vivo. This technique is considered a highly sensitive method for the assessment of GAG levels in cartilage and in intervertebral discs.

Additionally, on the basis that altered glycosylation is a critical hallmark of cancer development, Song et al. [36] applied CEST as a ‘label-free’ cellular imaging method for assessing the different protein glycosylation levels that are expressed in cancers. Ex vivo protein and cell experiments, as well as in vivo animal experiments demonstrated the differentiation of malignant tumors that were expressing under-glycosylated mucin-1 (uMUC1) from uMUC1 negative tumors.

2.3.4. Aliphatic Protons

The NOE was discovered in 1951 by Albert Overhauser [38], which is dipole-dipole coupling that occurs when the spatial distance of two nuclei is smaller than a critical value, manifesting as a change in the NMR signal intensity in one of the two nuclei. For many years, CEST studies focused on metabolites that were featuring positive frequency offsets on the Z-spectra. In 2007, Ling et al. identified a signal drop that was centered at \(-3.5\) ppm on Z-spectra (up-field from the water) and assigned it to NOE [37]. More specifically, the NOE signal derives from magnetization transfer between free water and bound water that is connected with aliphatic chains \((\text{-CH}_2\text{-})_n\) on lipids. At 3 T clinical field strength, NOE could induce an up to 10% water signal drop and show a clear Z-spectra ‘dip’ for the human brain. Therefore, it is considered a promising method for imaging lipid metabolism in various diseases [39].

While in most cases NOE imaging is used to detect lipids, it also has the potential to recognize other molecules. For instance, the glycogen NOE (glycoNOE) signal at around \(-1\) ppm is related to glycogen concentrations [34].

3. Technical Issues for Non-Brain Tumor Imaging

To describe the methods and parameters that were employed in the current CEST clinical acquisition and analyses protocols, Table 1 lists the common parameters for all of the studies that were involved in the imaging of various tumor types. Among all of the 43 studies, only 5 studies in breast cancer imaging were investigated at 7 T human scanners, whereas the remaining studies were all performed under 3 T field strength in clinical routine MR scanners. In addition, only 4 studies had a patient population larger than 100, while the rest had a patient number smaller than 100.

The sub-millimeter in-plane resolution can be achieved for a breast cancer study performed at 7 T [40], and a 1–2 mm in-plane resolution has been proven to be feasible for several types of tumor at 3 T scanners. This suggested that the much higher sensitivity of CEST could be achieved over the MR spectroscopy for imaging tumor metabolism. Except
for 5 studies that scanned longer, the acquisition time was usually within 7 min. This also reflected the feasibility of CEST for clinical use.

Table 1. CEST acquisition and analysis methods/parameters in non-brain tumor imaging *.

| CT   | Year | SN  | Saturation Preparation | Resolution (mm$^3$) | AT (s) | Readout Sequence | Quantification Metrics | Study |
|------|------|-----|------------------------|---------------------|--------|------------------|------------------------|-------|
|      |      |     |                        |                     |        |                  |                        |       |
|      |      |     |                        |                     |        |                  |                        |       |
| Breast | 2021 | 51  | PT                     | 3500                | 2000   | 0.9              | 2.0                    | 1.2 × 1.2 × 5          | 258   | TSE               | LF; MTR$_{asym}$ | [41] |
|      | 2019 | 21  | PT                     | 500                 | 1      | 1.7 × 1.7 × 4    | 3D-GRE                | LF; MTR$_{asym}$       | [44] |
|      | 2018 | 15  | CW                     | 500                 | 1.2    | 2 × 2 × 5        | 2D-Dixon              | LF; MTR$_{asym}$       | [45] |
|      | 2018 | 9   | PT                     | 4 s                 | 2      | 2.3 × 1.0 × 6.8  | GRE                    | LF; MTR$_{asym}$       | [46] |
|      | 2016 | 15  | PT                     | 75                  | 1      | 1.0 × 1.3 × 3.0  | N/A                   | 3D-GRE; Dixon           | LF; MTR$_{asym}$       | [47] |
|      | 2015 | 10  | PT                     | 25                  | 1      | 1.0 × 1.0 × 6.0  | N/A                   | 3D-GRE                 | LF; MTR$_{asym}$       | [48] |
|      | 2013 | 6   | PT                     | 400                 | 3      | 3 × 3 × 6        | 300                   | Turbo field echo        | LF; MTR$_{asym}$       | [49] |
|      | 2013 | 13  | PT                     | 962.5               | 0.5    | 2.5 × 2.5 × 5.0  | 402                   | N/A                    | LF; MTR$_{asym}$       | [50] |
|      | 2011 | 6   | PT                     | 100                 | 1.5    | 2.7 × 1.5 × 3.0  | 6.9 × 1.5 × 3.0       | 1.4 × 1.5 × 3.0        | N/A   | 3D-GRE; Dixon     | LF; MTR$_{asym}$       | [51] |
| Cervix | 2019 | 76  | PT                     | 2000                | 2.0    | 0.3 × 0.3 × 5.0  | 156                   | EPI                    | LF; MTR$_{asym}$       | [52] |
|      | 2019 | 32  | PT                     | 2000                | 2.0    | 2.0 × 2.0 × 5.0  | 406                   | SPIR; 3D-TSE APTw       | [53] |
|      | 2019 | 124 | PT                     | 2000                | 2.0    | 2.5 × 2.5 × 5.0  | 453                   | SPIR; 3D-TSE APTw       | [54] |
|      | 2019 | 31  | PT                     | 2000                | 2.0    | 2.0 × 2.0 × 5.0  | 406                   | SPIR; 3D-TSE APTw       | [55] |
|      | 2021 | 33  | PT                     | 2500                | 1.7    | 2.3 × 1.9 × 5.0  | 246                   | TSE                    | LF; MTR$_{asym}$       | [56] |
|      | 2021 | 80  | PT                     | 500                 | 2.0    | 2.8 × 2.8 × 5.0  | 156                   | 2D-EPI                 | LF; MTR$_{asym}$       | [57] |
| Lungs | 2021 | 54  | PT                     | 2000                | 2.0    | 2.5 × 2.5 × 5.0  | 453                   | 3D-TSE; SPIR APTw       | [58] |
|      | 2019 | 20  | PT                     | 2000                | 2.0    | 2.0 × 2.0 × 5.0  | 406                   | SPIR; 3D-TSE APTw       | [59] |
|      | 2018 | 32  | PT                     | 500                 | 2.0    | 1.8 × 1.8 × 5.0  | 140                   | 2D-GRE                 | APTw; MTR$_{asym}$     | [60] |
|      | 2021 | 100 | PT                     | 500                 | 2.0    | 2.2 × 2.2 × 5.0  | 156                   | EPI                    | LF; MTR$_{asym}$       | [61] |
| Prostate | 2019 | 7   | PT                     | 4800                | 0.92   | 2.2 × 2.2 × 4    | 342                   | TSE; SPIR               | LF; MTR$_{asym}$       | [62] |
|      | 2019 | 1   | PT                     | 40                  | 2.5    | 2.18 × 2.22 × 10.0 | 170 TSE; SPIR       | Z-spectra; glucoCEST signal | [63] |
|      | 2016 | 141 | PT                     | 500                 | 2.0    | 1.8 × 1.8 × 5.0  | 140                   | 2D-GRE                 | APTw; MTR$_{asym}$     | [64] |
|      | 2011 | 12  | PT                     | 496                 | 3.8    | 1.8 × 2.2 × 6.0  | 214                   | TSE                    | APTw; MTR$_{asym}$     | [65] |
| Ovary | 2017 | 1   | PT                     | 991                 | 1.5    | N/A               | 1425                  | Turbo-FLASH APTw       | AcidoCEST; LF; MTR$_{asym}$ | [66] |
Table 1. Cont.

| CT          | Year | SN  | Pulse Type | $T_{\text{sat}}$ (ms) | Resolution (mm$^3$) | AT (s) | Readout Sequence | Quantification Metrics | Study       |
|-------------|------|-----|------------|-----------------------|---------------------|--------|------------------|------------------------|-------------|
| Rectum      | 2021 | 53  | CW         | 2000                  | 1.8 × 1.8 × 5       | N/A    | 3D-TSE Dixon     | MTRasym                | [67]        |
|             | 2020 | 43  | qCW        | 2000                  | 1.8 × 1.8 × 5.0     | 270    | 3D-TSE Dixon; SPIR | APTw                   | [68]        |
|             | 2020 | 61  | CW         | 2000                  | 1.8 × 1.8 × 5.0     | 270    | TSE; Dixon       | APTw                   | [69]        |
|             | 2019 | 17  | PT         | 500                   | 1.8 × 1.8 × 5.0     | 140    | TSE              | MTRasym                | [70]        |
|             | 2018 | 22  | PT         | 500                   | 1.8 × 1.8 × 5.0     | 140    | TSE              | MTRasym                | [71]        |
| Liver       | 2021 | 20  | PT         | 28                    | 1.88 × 1.88 × 5.0   | 391    | GRE              | MTRasym                | [72]        |
|             | 2020 | 56  | N/A        | N/A                   | 3.13.1 × 5.0        | N/A    | EPI              | MTRasym                | [73]        |
| Salivary gland | 2019 | 32  | PT         | 830                   | 1.0 × 1.5 × 6       | 261    | 2D-TSE           | MTRasym                | [74]        |
| Head & neck | 2021 | 36  | PT         | 2000                  | 2.5 × 2.5 × 5.0     | 160    | 3D-TSE           | MTRasym                | [75]        |
|             | 2021 | 42  | PT         | 2000                  | 1.8 × 1.8 × 5.0     | 112    | 2D-GRE           | APTw                   | [76]        |
|             | 2019 | 38  | PT         | 70                    | 2.0 × 2.5 × 6.0     | 245    | 3D-EPI           | APTw                   | [77]        |
| Lung & Thoracic | 2019 | 29  | PT         | 830                   | 2.2 × 2.2 × 6       | 261    | TSE              | MTRasym                | [78]        |
|             | 2014 | 10  | CW         | 200                   | 2.0 × 2.0 × 4.0     | 120    | TSE              | APTw                   | [79]        |

* Only CEST related properties of the studies are listed. * The magnetic field intensity of these studies was 7 Tesla, while that of the other studies was 3 Tesla. CT = cancer type; SN = subject number; $T_{\text{sat}}$ = saturation time; AT = acquisition time; PT = pulse train; TSE = turbo spin echo; LF = LF; MTRasym = magnetization transfer ratio asymmetry; EPI = echo planar imaging; APTw = APT-weighted; AREX = apparent-exchange-dependent-relaxation; CW = continue wave; GRE = gradient echo; SPAIR = spectral attenuated inversion recovery; PTR = proton-transfer-ratio; = metrics corrected for $B_1$ efficiency; SPIR = spectral pre-saturation with inversion recovery; TurboFlash = Turbo Fast Low-angle Shot; qCW = quasi-continuous wave.

For the quantitation metrics, approximately half of the studies used APTw, i.e., MTRasym (3.5 ppm). This is because APTw is the only commercial CEST imaging protocol that is available on 3 T clinical MR scanners and demonstrated a correlation with the histological grades in brain tumors [6]. Other metrics included Lorentzian fitting (LD), MTRasym at other offsets than 3.5 ppm, and AREX, which were a bit more complicated but allowed better differentiations of signal sources, for example the amide signal from proteins/peptides versus NOE from lipids.

Additionally, body CEST imaging faces several common technical issues, which attracted many efforts in acquisition sequences and analysis methods.

### 3.1. Fat Suppression

Compared with brain imaging, body imaging always needs to consider the interference from fat. A total of three types of sequences were employed in Table 1, which were Dixon-based methods, chemical shift-based methods (SPAIR and SPIR), as well as the use of a frequency-specific excitation pulse for water imaging. Zhang et al. [45] developed CEST-Dixon imaging sequence, allowing for both water-fat separation and $B_0$ mapping. For different types of breast cancer tissue, the CEST-Dixon sequence showed homogenous fat removal in water-only images, and also allowed the imaging of hydroxyl protons post $B_0$ correction. The Dixon-type sequence was also employed in CEST imaging for rectum tumors and uterus tumors. SPIR or SPAIR are the most commonly used methods for fat suppression, which added a fat-selective inversion pulse and a read signal when fat recovered to zero.
3.2. B₀ and B₁ Corrections

As a chemical shift-based method, CEST acquisition and analysis are very fragile to B₀ field inhomogeneity. Local B₀ shift will cause an inaccurate saturation frequency, artifacts, or image deformation for gradient-echo based imaging sequences, as well as quantification errors. Therefore, CEST usually needs to sweep a range of saturation frequencies and perform a voxel-by-voxel correction of the B₀ shift.

Compared with the brain, B₀ inhomogeneity is more severe in body CEST imaging which has larger field of view and heterogeneous tissue composition. To correct the B₀ shift proper sequence and correction methods are required for reliable imaging performance. The B₀ shift map could be acquired using the above Dixon method, fitted from the interpolated Z-spectra or a water saturation shift referencing (WASSR) [83] method. Dula et al. [48] implemented a simulation for the optimization of CEST detection using amide and GAG in fibroglandular breast tissues. Compared with other quantification metrics, MTRasym methods are usually more susceptible to B₀ inhomogeneity.

Although not as critical as B₀ correction for lower saturation power, B₁ inhomogeneity affects signal quantification, especially when a large B₁ is required for detecting fast-exchanging species. B₁ corrections involves two steps: B₁ mapping and the calculation of real contrasts. The B₁ mapping methods include a double-angle method [84,85], Bloch-Siegert shift method [86], WASABI [87], and so on. The subsequent calculation can be mainly attributed to three different strategies. The first is to interpolate a value corresponding to rB₁ (relative B₁, defined as real B₁/nominal B₁) = 1 on the MTR-rB₁ plane or Z-rB₁ plane pixel by pixel [88]. The second is to fit the data on the MTR-rB₁ or Z-rB₁ plane with a selectively constructed function for each pixel group, divided based on the tissue types of T₁ values [89,90]. The third is to perform Bloch-McConnell fitting on the Z-spectra and generate new Z-spectra with B₁ values that are corrected from real ones to nominal ones [91].

3.3. Motion-Related Acquisition and Corrections

Human organs, such as the liver and lung, deform significantly with respiration, often causing severe motion artifacts in MRI without special designs. CEST usually applies a non-geometry specific 3D saturation pulse, thus the saturation is not affected much by motion but the water readout is. Therefore, a fast image readout was chosen, such as echo planar imaging (EPI), rapid imaging with refocused echoes (RARE), fast spin echo (FSE), and/or fast imaging with steady-state precession (FISP) [6,34–36]. As shown in Table 1, out of the three papers on liver and the two on lung, four used FSE [74,75,81,82] and one used EPI [73]. Besides a fast readout, respiration-gated design [81,82] or breath holding [73,74] are still required to reduce motion during acquisition.

Volumetric navigators (vNavs), a sequence block that is applied before the saturation pulses, can help to perform real-time motion correction for CEST [92]. As yet, vNavs have not been translated to body imaging, which may be studied in the future.

4. Applications

4.1. CEST Imaging of Breast Cancer

Breast cancer tops the list for cancer mortality for both women and the total population [93]. Our survey of the literature shows that approximately 2/7 of the clinical CEST/APT tumor studies involved breast cancer. This research has largely focused on two clinical aspects, the first involving the differentiation between the tumor subtypes and grades and secondly, for assessing the treatment responses.

4.1.1. Differentiation of Malignant from Benign Lesions

Schmitt et al. [51] reported that for three out of six patients, the regions of high CEST signal intensity matched well with tumor areas that were determined by DCE-MRI on a 3 T MRI. Significantly higher MTRasym values at 1.8 ppm were detected in tumor tissue compared to normal breast tissue for these three patients. However, the high fat
content that is associated with breast tissue may cause artifacts, resulting in a misdiagnosis. To remove fat interference, Zhang et al. [45] developed a CEST-Dixon sequence that was validated by breast cancer imaging at 3 T, which could well correct $B_0$ inhomogeneity and obtain hydroxyl CEST maps at 1ppm (Figure 3). It was found that the $\text{MTR}_{\text{asym}}$ at 1, 2, and 3.5 ppm for estrogen receptor (ER)-negative invasive ductal carcinoma (IDC) tissue was higher than those for ER-positive IDC, benign and normal tissues. However, there were no significant signal differences among the ER-positive IDC, benign, and normal tissues.

Loi et al. [40] employed relaxation compensated CEST signals for breast cancer characterization and quantified those using $\text{MTR}_{\text{asym}}$. They found that amide CEST signals (3.5 ppm) as well as guanidyl CEST signals (2.2 ppm) were increased in tumor tissue compared to the normal appearing fibroglandular breast tissue of patients and healthy volunteers. Notably, APT and guanidyl CEST signals in fibroglandular tissue were not different between patients and healthy volunteers. However, Meng et al. [42] found that the $\text{MTR}_{\text{asym}}$ (3.5 ppm) values of malignant tumors were significantly lower than those in benign lesions, also showing a weak correlation with pathological grade.

4.1.2. Comparisons with Pathological Grades

Zaric et al. [44] compared $\text{MTR}_{\text{asym}}$ values with the histological grades of breast tumors, reporting a significant increase in $\text{MTR}_{\text{asym}}$ between Grade 1 and Grade 3 lesions. In contrast to other studies which assigned a constant offset (mainly 3.5 ppm), this paper did not use the same frequency offset for all patients. Instead, the highest values on the $\text{MTR}_{\text{asym}}$ spectrum were selected, with the peak offset varying from 1.2 ppm to 3.55 ppm. In contrast, Meng et al. [42] found that the $\text{MTR}_{\text{asym}}$ (3.5 ppm) values did not provide good correlations with the pathological grade ($r = 0.371$). Zaric et al. [44] further studied the relationship between $\text{MTR}_{\text{asym}}$ values and cell proliferation, and found a strong positive correlation between $\text{MTR}_{\text{asym}}$ and the Ki-67 proliferation index. However, Loi et al. [40]...
reported that Ki-67 only moderately correlated with the amide and the guanidyl CEST signals. Zhang et al. [45] used CEST-Dixon to characterize different types of breast cancer tissue and found that in the three frequency ranges that were studied, 1 ppm CEST signals \((\text{MTR}_{\text{asym}})\) were the highest in ER-negative IDC cases, exhibiting the highest correlation with Ki-67 and the largest differences among each of the tissue groups.

4.1.3. Assessment of Treatment Responses

To assess the response to neoadjuvant chemotherapy (NAC), Klomp et al. [50] imaged breast tissues with 3 T APT-MRI, and showed that the APT values that were calculated by the Lorentzian difference increased during disease progression while conversely decreased in patients that showed partial or complete responses. Krikken et al. [46] further tested the ability of CEST to evaluate early response to NAC in breast cancer patients. For six out of the ten lesions that were analyzed, significant differences were found between the APT signals that were calculated by three-pool Lorentzian fitting acquired pre- and post-NAC. However, one of the two pathologically validated complete response cases showed no significant difference in pre- and post-NAC APT signals. Moreover, different pathological responses to NAC treatment showed no significant differences in changes in APT signals. Zhang et al. [41] found that quantitative APTw MRI depended on optimizing acquisition saturation powers and analysis methods, and also monitored the treatment effects but did not differentiate participants with triple-negative breast cancer who had a pathologic complete response (pCR) from those with non-pCR.

One of the consequences of breast cancer resection involves lymphedema in the patients’ upper extremities, which may be relieved by lymphatic mobilization therapy. Donahue et al. [47] found APT signals (both standard asymmetry and Lorentzian asymmetry) had no significant difference between the right and left arms of healthy controls but values increased in the patient’s arm that was affected by lymphedema. Crescenzi et al. [43] found that the proton transfer ratio (PTR, defined as \(1-Z'\), where \(Z'\) is the Z-spectra after \(B_1\) correction) APT significantly correlated with \(T_1\) and BMI (body-mass-index) in controls, and the lymphedema stage in breast cancer treatment-related lymphedema (BCRL) participants. The post-therapy PTR of APT significantly increased in the affected arm of BCRL participants, consistent with the treatment effects that were from mobilized lymphatic fluid.

4.2. Pelvic Tumors

Pelvic tumors include those of the cervix uteri, corpus uteri, ovary, and prostate, and all ranked among the top ten in the list of cancer incidences and mortality rates worldwide in 2020 [93]. All of the studies were performed using 3 T MR scanners.

4.2.1. Cervical Cancer

All cervical cancer studies reported used \(\text{MTR}_{\text{asym}}\) (3.5 ppm), i.e. APTw image, for CEST quantification. He et al. [54] compared 75 patients with cervical lesions (mostly squamous cell carcinoma and adenocarcinoma) against 49 healthy volunteers, finding that the APT values of cervical cancer and normal cervical stroma showed highly significant differences \((p < 0.0001)\). Typical images were shown in Figure 4.
Figure 4. (a) APTw image of a 47-year-old woman with cervical squamous cell carcinoma; the APT value was 2.68. (b) APTw image of a 46-year-old woman with a normal cervix; the APT value was 1.76. Reproduced with permission from John Wiley and Sons 2019 (DOI: 10.1002/jmri.26710) [54].

In a study of cervical squamous carcinomas (CSCs), Sun et al. [53,54] found that the APT values (MTR asym(3.5ppm)) of the squamous cell carcinoma of the cervix (SCCC) were higher than normal cervical stroma. Significant differences were similarly found in the APT values between the moderately- to well-differentiated CSC and poorly differentiated CSC cases. The APT values for histologic Grades 1 to 3 were also significantly different.

Using a scanner from a different manufacturer than above studies, Meng et al. [52] found that APT values in cervical cancer cases were higher than those of normal cervixes. The APT value of the cervical adenocarcinoma group was higher than that of the CSC group. The APT values were found to gradually increase between the high-, middle-, and low-differentiation cases of CSC, but only statistically significant differences were measured between the high- and low-differentiation groups (p < 0.05). No significant difference was found between the Grade 1 and Grade 2 tumors, or between well- and moderately-differentiated cancers in all of the above studies.

4.2.2. Endometrial Carcinoma

A total of five groups have contributed reports that were involving cervical cancer and endometrial carcinomas along with healthy uterine tissues. APT values changed with cancer type [56], histology grade [60], proliferation, as well as menstrual cycle. The APT method was co-studied with other fMRI methods [57].

Ochiai et al. [56] evaluated the efficacy of APT imaging in the differentiation of type I and type II uterine endometrial carcinomas in a 33-patient study. Results show that APT imaging has the potential to determine the type of endometrial cancer. Takayama et al. [60] compared APT values with the histological grades of endometrioid endometrial adenocarcinoma (EEA), the most common type of endometrial carcinoma. With a Spearman correlation coefficient of 0.55 reported, the average APT values of Grade 1 to 3 EEA were 2.2% ± 0.2, 3.2% ± 0.3, and 3.7% ± 0.3, respectively. With the typical APTw images and the corresponding histology pictures shown in Figure 5, population-wise the APT values of Grade 3 EEA cases were significantly higher than those of Grade 1 (p = 0.01), but other pairwise comparisons did not reveal any significant differences (p = 0.06–0.51). He et al. [58] compared the APT values of low-proliferation (Ki-67 < 30%, n = 8) and high-proliferation cases (Ki-67 > 30%, n = 14) of type I endometrial carcinoma, showing there was a moderate positive correlation between the Ki-67 labeling index and APT values (r = 0.583, p = 0.004). Sun et al. [59] investigated 20 healthy women of childbearing age and found that the APT values did not differ significantly between the endometrium and myometrium during any phase. In each uterine structure, the APT values decreased from the secretory phase to the proliferative phase and reached the lowest values in the menstrual phase. However, the APT values did not differ significantly between the menstrual phase and proliferative phases. Inter-individual variation in the APT values for a given zone or phase ranged from 1.86% to 2.75%. This study indicated that changes that are caused by the menstrual cycle should be considered for CEST imaging of the uterus.
Figure 5. Images of a 71-year-old woman (patient 1) with Grade 1 EEA and a 50-year-old woman (patient 2) with Grade 3 EEA. APT image of EEA fused with fat-suppressed proton density–weighted-imaging of patient 1 (a) and patient 2 (c), as well as the microscopic image of hematoxylin-eosin (H&E) staining of EEA (original magnification, ×200) of patient 1 (b) and patient 2 (d). The tumors of the two patients show inhomogeneous SIs on the APT image, and the averaged APT SIs obtained by the two readers were 1.7% for patient 1 and 3.7% for patient 2, respectively. The microscopic image of patient 1 shows the proliferation of well-differentiated EEA cells, arranged in irregular glands and tubules; The cell morphology, density and distribution features indicate Grade 1 EEA. The microscopic image of patient 2 shows the proliferation of moderately- to poorly-differentiated EEA cells, arranged in solid and glandular patterns; The cell morphology, density and distribution features indicate Grade 3 EEA. Reproduced with permission from Radiological Society of North America 2018 (DOI: 10.1148/radiol.2017170349) [60].

Meng et al. also studied endometrial carcinoma (EC) by using APT and the other methods [57]. The authors found that the APT values were significantly less in low-risk cases compared to those of higher risk, and moreover, that the APT values, diffusion coefficient (D), and mean kurtosis (MK) were independent predictors of risk stratification. Nevertheless, the combination of these three parameters was able to better identify low- and high-risk groups compared to the individual measures.
4.2.3. Prostate Cancer

CEST has been used in prostate cancer classification and tumor characterization. Jia et al. [65] found that MTR_{asym} values in prostate cancer ROIs were significantly higher than for those in the peripheral zone benign regions. This is an encouraging indication that APT MR imaging may be feasible for prostate cancer detection and has the potential to distinguish cancerous from non-cancerous tissue. Takayama et al. [64] studied the relationship between APT values and prostate cancer Gleason scores (GS), finding that the mean ± SD APT values varied for GS-6 (2.48 ± 0.59), GS-7 (5.17 ± 0.66), GS-8 (2.56 ± 0.85), and GS-9 (1.96 ± 0.75), respectively. This is a progressive grading score, but the APT value of the GS-7 group was highest, with significant differences measured between the GS-6 and GS-7 groups and the GS-7 and GS-9 groups (p < 0.05). Yin et al. [61] also found that diffusion kurtosis imaging (DKI) and APT imaging are valuable in the diagnosis of prostate cancer (PCa) and demonstrated a strong correlation with the Gleason Score, which had great significance in the risk assessment of PCa.

4.2.4. Ovarian Cancer

AcidoCEST can be used to measure the extracellular pH (pHe) of human tumors, which may reflect the metabolic status of the tumors, or be used to detect tumors among normal tissue backgrounds. Jones et al. [66] found that in one patient with metastatic ovarian cancer, the average pHe value of three adjacent tumors was 6.58, whereas the average pHe of the kidney was 6.73. Bloch equations were used to fit the CEST spectra to get a pHe value of the imaging tissue. An FDA-approved clinical contrast agent for CT clinical studies named Iopamidol (Isovue, Bracco Imaging, Inc., Milan, Italy) was used in this study for CEST imaging, whose signal was linearly correlated with pH values. Lorentzian fitting was also used in this study.

4.3. Digestive Tumors

Digestive tumors include rectal, liver, and salivary cancers. Both rectal and liver cancers appear in the top 10 list of cancer incidence and mortality rates worldwide in 2020 [93].

4.3.1. Rectal Cancer

Classification and tumor grading: Chen et al. [67] found that the combination of APTw and DWI may serve as noninvasive biomarkers for evaluating and identifying responses to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients.

Nishie et al. [71] studied 22 rectal cancer patients and reported significant differences in the average MTR_{asym} of tumors with diameters more than 5 cm and less than 5 cm. There were also significant differences between MTR_{asym} in moderately- versus well-differentiated adenocarcinomas. In contrast, the apparent diffusion coefficient (ADC) could not distinguish between groups that were classified by any pathological factor. Xian Liu’s group [68] applied APT MRI and DWI into the assessment of two important prognostic factors of rectal adenocarcinoma, which were the p53 status and Ki-67 index. The histological grade, T stage, and N stage were also evaluated. It was found in 43 patients that high-grade tumors, tumors of more advanced stage, and tumors with lymph node involvement showed significantly higher mean MTR_{asym} values. In contrast, ADC values were also significantly different in terms of different pT stages, but not in terms of pN stages or histological grades. Regarding the prognostic markers, p53 positive status was correlated with higher mean MTR_{asym} values, but not with ADC values. Notably, both MTR_{asym} and ADC values were significantly different between tumors with low and high Ki-67 expression status. Liu et al. [69] also conducted a study to compare the utility of APT MRI and that of diffusion kurtosis imaging (DKI) in predicting several pathologic factors for rectal adenocarcinoma, which were WHO grade, pT stage, pN stage, and EMVI status. It was found that significantly higher mean APTw signal intensity (SI) was correlated with high-grade tumors, as well as T3 stage tumors with lymph node metastasis or EMVI-
positive status. Compared with kurtosis, diffusivity, and ADC, APTw SI was a better discriminating index of tumor grading.

Various studies compared the CEST parameters with the Ki-67 proliferation index in histology. The CEST-Dixon sequence was used at 3 T for rectal tumors [68]. The mean APTw had a positive correlation with Ki-67. It also had a significantly higher diagnostic ability for the differentiation of the high Ki-67 expression tissue group than ADCmean. However, this conclusion may not apply to mucinous adenocarcinoma or heterogeneous tumors [71]. Another study on 7 T calculated CEST MTR asym values at three different offsets for breast cancer also reported a strong positive correlation between the largest MTR asym value in each patient and the Ki-67 index. However, this study did not use the Dixon method for fat suppression. Instead, a frequency-dependent water excitation pulse was used [44].

Assessment of treatment response: Nishie et al. [70] examined 17 patients with locally advanced rectal cancer who underwent neoadjuvant chemotherapy. According to the treatment responsiveness, the mean MTR asym of lesions of patients showing limited responses was significantly higher than those who responded to therapy. Analysis of the predictive ability of MTR asym for tumor responses showed values of 75% sensitivity and 100% specificity.

4.3.2. Liver

Tumor detection: Tang et al. [72] performed ioversol-based pH mapping on a 3 T scanner. The CEST-related signal was separated using MTR asym at 4.3 ppm and the pH effect was measured by a specially designed ratiometric value that was calculated from the signals that were obtained at two flip angles (Figure 6). The logarithm of the ratiometric value was found to be proportional to pH values in vitro and thus the pH values can be estimated. In a 15-patient study, the estimated pH values were significantly lower in hepatic carcinomas (6.66 ± 0.19) than in the normal liver tissue (7.31 ± 0.12; p < 0.0001). However, in a 5-patient study, no significant differences (p = 0.5587) were found between hepatic hemangioma (7.34 ± 0.09) and normal tissues (7.37 ± 0.08).

Figure 6. pH values of hepatic hemangioma using dual-power CEST MRI. (a) A representative image of a patient with hepatic hemangioma. After injection of a CT agent (Ioverol), CEST images acquired with flip angles of 60° (b) and of 350° (c), respectively. (d) The pH map for hepatic hemangioma; the CEST pH was consistent with the surrounding liver tissue, confirming the hemangioma to be benign. Reproduced with permission from Frontiers 2020 (DOI: 10.3389/fonc.2020.578985) [72].
Predicting histological grade: Lin et al. [74] found that the APTw imaging is a useful imaging biomarker that complements DWI for the more accurate and comprehensive hepatocellular carcinoma (HCC) characterization. Both APTw and DWI had good diagnostic performance in differentiating the high- from the low-grade HCCs, with areas under the curves of 0.814 and 0.745, respectively. Moderate correlations existed between the APTw values and histological grades, as well as the ADC values and histological grades.

Assessment of treatment response: Jia et al. [73] constructed a protocol to predict the intermediate-stage hepatocellular carcinoma response to trans-arterial chemoembolization, in which APT imaging at 3 T was an important step. APT was quantified with MTR asym. In the three groups (i.e., tumor, peritumoral, and normal tissues), the APT signals were in good agreement within each group and significantly different between groups.

4.3.3. Salivary Gland Tumors

Tumor detection: Yu et al. [78] found that APTw MRI is feasible for use in head and neck tumors and is a valuable imaging biomarker for distinguishing malignant from benign lesions. Yuan et al. [79] also found that APTw MRI was feasible for use in the head and neck regions at 3 T in clinical applications. Chen et al. [75] found that most APTw images of tumor lesions in parotid glands had an acceptable image quality (Figure 7), hence were feasible for diagnostic use.

Figure 7. An APTw example showing excellent image quality. A round lesion was found in the right parotid gland of a 65 year-old male, as shown on T2WI (a). The corresponding APTw image of the same slice is shown in (b). The image quality for this APTw map in terms of integrity and hyperintensity artifacts on the lesion was scored as 4 and 4, respectively. The lesion was considered as being in the trustable group. The average APTw value of the lesion was 1.94% for the ROI w2, drawn avoiding the surrounding hyper intensity artifacts in the ROI w1. The arrows mean APTw values in ROI. Reproduced with permission from AME 2021 (DOI: 10.21037/qims-20-675) [75].

Comparison with other methods Takumi et al. [76] reported that MTR asym values of APT in malignant lesions were significantly higher than for benign lesions ($p = 0.047$). However, no significant differences were found in ADC or tumor blood flow (TBF) between benign and malignant lesions in the same patients. The accuracy of the three parameters combined was significantly higher than that of each parameter alone. It was concluded from this study that the combination of ADC, TBF, and MTR asym was more helpful in differentiating malignant from benign salivary gland lesions. Bae et al. [77] found in a 38 subjects study that the APTw signals for major salivary gland tumors were significantly higher in malignant tumors than in benign ones in terms of maximum, mean, and median measures. Notably, the diagnostic performance of APTw signals was superior compared...
with the combination of DWI and DCE-MRI, indicating that APTw-MRI could benefit the differential diagnosis of major salivary gland tumors in the clinic.

4.4. Lung Cancer

Lung cancer is on the top 10 list of the cancer incidence and mortality rates worldwide in 2020 [93].

Differentiation of malignant from benign pulmonary nodules: A study of 82 patients with pulmonary nodules by Ohno et al. [81] measured APTR using MTR$_{\text{asym}}$ at 3.5 ppm. It was shown that although the sensitivity of ADC was significantly higher than that of APTR ($p = 0.002$) along with FDG-based SUV$_{\text{max}}$ measurements (maximum value of standard uptake value; $p = 0.004$), the specificity of APTR and SUV$_{\text{max}}$ was significantly higher than for ADC ($p < 0.05$). Moreover, the sensitivity of combined APTR with SUV$_{\text{max}}$ was significantly higher than either APTR ($p = 0.001$) or SUV$_{\text{max}}$ ($p = 0.002$) alone. Additionally, the specificity and accuracy of combined APTR and SUV$_{\text{max}}$ were significantly higher than for ADC (specificity: $p = 0.002$, accuracy: $p = 0.008$). Together, these data confirm the effectiveness of CEST in differentiating benign from malignant nodules.

Assessment of treatment response: Jones et al. [80] developed a retrospective respiration-gated method that was based on phantom studies as well as three patients with lung cancer. The method was then applied to four lung cancer (or mesothelioma) patients to assess their reactions after radiation therapy and/or chemotherapy. The results indicated more precise measurements using retrospective respiration-gated analysis in all cases compared to non-gated analysis methods, showing this approach can improve the CEST MRI evaluations of tumors and organs that are affected by respiratory motion. The preliminary clinical study showed a large increase in MTR$_{\text{asym}}$ at 3.5 ppm after radiation therapy, a small increase or decrease in MTR$_{\text{asym}}$ after chemotherapy, and mixed results with combined chemoradiation therapy, suggesting that the CEST MRI may be more sensitive to radiation therapy than to chemotherapy.

Characterization of thoracic lesions: Ohno et al. [82] studied malignant and benign thoracic lesions in 21 patients and found that MTR$_{\text{asym}}$ for malignant tumors was 3.56% ± 3.01, significantly higher than that for benign lesions (0.33% ± 0.38, $p = 0.008$). Lung cancer MTR$_{\text{asym}}$ values were significantly lower than for other thoracic malignancies (2.16% ± 1.41 versus 6.71% ± 3.46, respectively; $p = 0.005$). Moreover, among lung cancers, MTR$_{\text{asym}}$ for adenocarcinomas was significantly higher than for squamous cell carcinomas shown in Figure 8 (2.88% ± 1.13 versus 0.71% ± 0.17, respectively; $p = 0.02$).

![Figure 8. Squamous cell carcinoma in a 66 year-old man. (a) Axial thin-section CT image (lung window setting) shows a left hilar mass, with obstructive pneumonia. (b) Sagittal APT-weighted CEST MR map shows a left hilar mass (arrow) with low MTR$_{\text{asym}}$ (at 3.5 ppm) and relatively high MTR$_{\text{asym}}$ (at 3.5 ppm) of the surrounding obstructive pneumonia. Reproduced with permission from Radiological Society of North America 2016 (DOI: 10.1148/radiol.2015151161) [82].](image-url)
4.5. Comparison with Other Functional MRI Methods

In many above studies, the diagnosis capability of APTw-MRI was compared with other functional MRI methods including DWI and contrast-enhanced images. To further clarify, Table 2 summarized the basic principle, quantification parameters, application in tumor imaging, as well as the advantages and disadvantages, for the three MRI-based imaging methods.

Table 2. Comparison of MRI-based imaging methods.

| Imaging Type | APTw-MRI | DWI-MRI | DCE-MRI |
|--------------|----------|---------|---------|
| **Full name** | Amide proton transfer-weighted MRI | Diffusion-weighted imaging MRI | Dynamic contrast-enhanced MRI |
| **Target** | Amide proton constituents | Cell density, tumor microstructure | Contrast enhancement kinetics |
| **Imaging principle** | Based on the effect of CEST between free water and mobile proteins or peptides backbones; amide proton constituents abundant in tumors. | Measuring the random Brownian motion of water molecules within a voxel of tissue. Highly cellular tissues exhibit lower diffusion coefficients. | Uses the $T_1$ relaxation characteristics of gadolinium contrast agents to model the pharmacokinetic distribution of contrast between the vasculature and interstitial space. Time-intensity curve (TIC); $k_{ep}$ (the exchange of the contrast agent between the two compartments) |
| **Parameter** | APT signal intensity (APT SI) | Apparent diffusion coefficient (ADC) | Assess the therapeutic response of tumor. |
| **Clinical application in tumor imaging** | Diagnosis tumor, predict tumor response to treatment, assessment of prognostic factors | Tumor grading, diagnosis and prognosis; Assessing the proliferation status of several cancers | Important for the clinical evaluation of EEA, especially for assessment of the depth of myometrial invasion. [60] |
| **Advantages** | Needs no exogenous contrast agent; Quantitative imaging parameters correlate with histopathology or oncogenic protein markers, such as p53 and Ki-67 index [94] | Effective in the differentiation with high diagnostic accuracy | The golden standard of neovascularization; Effective in the differentiation with high diagnostic accuracy; |
| **Disadvantages** | APT imaging is often prone to artifacts resulting from system Instability [42] | ADC diagnostic and prognostic capacity is reduced by the complex components in tumor interstitial regions | Needs exogenous contrast agent; Contrast enhancement kinetics in tissue depend on several factors such as microvessel density and vascular permeability, which are not pathognomonic for some tumors like breast tumors [51] |

5. Discussion and Future Prospects

5.1. Advantages of CEST in Cancer Detection

CEST is a newly developed clinical MR imaging method. The key advantages of CEST imaging include:

1. As a sensitive chemical-shift based method, the spatial resolution could be close to the standard MR images.
2. Contrast could be turned “on” and “off” by the acquisition sequence, and “multicolor” imaging could be achieved in parallel with optical imaging.
3. CEST can detect both endogenous and exogenous agents. When this method detects the endogenous contents of lipids, mobile proteins/peptides, glycans, as well as small metabolites in tissue itself, CEST does not need to consider the delivery and targeted efficiency of agents. In addition, the surrounding normal tissue could be employed as an internal reference.
5.2. Challenges for Implementing CEST in the Clinic

However, there still are some challenges to be met for the future development and implementation of CEST.

(1) Saturation power and imaging time

For more practical clinical usage, CEST needs to be implemented with less saturation power and reduced imaging times. To meet the FDA-guided specific absorption rate requirements [40], CEST applications in humans may have a limited saturation pulse duration or duty cycle or RF amplifier for low power deposition. New excitation sequences could, therefore, potentially resolve the tradeoff between imaging quality and power usage.

With regard to shortening the scan times, there are at least two possible pathways: to reduce the number of scans that are necessary, or to acquire more scans in a defined time window. A short scan time strategy called SAFARI (a sequence of saturation with frequency alternating RF irradiation) has been reported as requiring only three image acquisitions while maintaining the specificity of CEST detection [95]. The MTRdouble method as proposed by Gochberg’s group [96] requires as few as three data points, which is more rapid than methods requiring a complete Z-spectrum. The multi-echo length and offset varied saturation (MeLOVARS) technique uses the idea of Look-Locker and obtains several echoes in each repetition period [97]. More saturation techniques such as these are needed to aid the development of CEST usage in the clinic.

(2) $B_0/B_1$ fluctuation effects

The CEST signal is sensitive to $B_0/B_1$ fluctuations or the movement artifact of organs, such as bowel motions [14]. Besides saturation techniques, data analysis methods also need to focus on removing the background effects that are caused by MT or NOE. Furthermore, optimized and standardized scan protocols for CEST MRI are necessary for clinical usage [33].

One point that needs to be raised is that the uniformity of the main magnetic field, $B_0$, is very important for CEST imaging, especially in vivo imaging. In addition, the uniformity of the saturation field strength, $B_1$, also affects CEST quantification especially for fast-exchanging protons, since CEST saturation efficiency is determined partially by $B_1$. On one hand, higher magnetic fields could achieve better SNR and frequency resolution, which is beneficial for CEST imaging. On the other hand, $B_0$ and $B_1$ inhomogeneity will increase under higher field strengths, therefore, proper $B_0$ and $B_1$ correction needs to also be considered. Notably, the larger field of view that is associated with body imaging is more challenging than brain imaging due to both the heterogeneous tissue composition and the $B_0$ and $B_1$ field inhomogeneity.

(3) Artifact elimination

The potential sources of artifact that are affecting the quantitative and qualitative discrimination of tissues are numerous and include fat or air in the imaging ROI; tissue movement during imaging caused by breathing, bladder filling, bowel movements; as well as errors caused by menstruation. As previously discussed, CEST-Dixon has been used to suppress fat artifacts [45]. Some motion-correction methods have also been developed [98–101], but there is still room for improvement in the scope of application and the correction performance. Thus, further studies are needed to improve artifact elimination.

(4) Interpretation of the results

For clinical usage, the relationship between CEST values and traditional histology characteristics need to be studied more thoroughly. Several studies [52,60] have reported that MTR$_{asym}$ values were related to the histological grade or could differentiate the grades of tumors. However, only MTR$_{asym}$ values of Grade 3 (or moderate- to well-differentiated) lesions were significantly different from Grade 1 or 2 (poorly-differentiated)
lesions. The difference between MTR\(_{\text{asym}}\) values of Grade 1 and 2 (or moderately- and well-differentiated) lesions or Grades 2 and 3 were not significant.

5.3. Future Prospects

As in Figure 1, CEST imaging of non-brain tumors is a fast-growing field. Except for endogenous APTw imaging, advanced sequences and the quantification of multiple CEST and NOE sources are under development [101]. There are also two types of clinically approved agents, glucose and CT agents, that have been investigated under high-field pre-clinical scanners (Table 3).

| Table 3. Preclinical studies. |
|-------------------------------|
| **Body Part** | **Year** | **MS (T)** | **Saturation Pulse** | **Resolution** | **AT** | **Technical Novelty** | **Study** |
|----------------|----------|-------------|----------------------|--------------|--------|----------------------|----------|
| Nasopharyngeal | 2021     | 3.0         | 0.8                  | 2            | 1.25 × 1.25 × 7 | 381      | MTR\(_{\text{asym}}\)| [102] |
|                | 2021     | 7           | 5                    | 1.5          | 0.3125 × 0.3125 × 1.5 | 128      | Contrast agents: voluven and dextran 70 | [103] |
|                | 2019     | 7           | 5                    | 1.5          | 0.39 × 0.39 × 4   | 793      | Integrating CEST contrast agents into nanocarriers | [104] |
|                | 2017     | 7           | 5                    | 1.5          | 0.234 × 0.234 × 1.5 | ~605     | Pharmaceutical excipients as contrast agents | [105] |
| Pancreas       | 2020     | 14          | 1                    | 3            | 0.2 × 0.2 × 1     | 1800     | Rare sequence; WASSR; | [106] |
|                | 2019     | 14          | 1                    | 3            | 0.2 × 0.2 × 1     | 1140     | Rare sequence; WASSR; | [107] |
|                | 2019     | 11.7        | 3                    | 1.8          | 0.4 × 0.4 × 1     | 300      | Contrast agent; RARE sequence; WASSR; | [108] |
|                | 2019     | 7           | 6                    | 3.5 T        | 0.05 × 0.05 × 2   | 180–240  | Iopamidol; acidoCEST | [109] |
|                | 2018     | 14          | 3                    | 2            | 0.2 × 0.2 × 1     | 1140     | RARE sequence; WASSR; | [110] |
|                | 2017     | 7           | 6                    | 4            | 0.469 × 0.312 × 2 | ~282     | Contrast agent: GR4Am-SA; catalyCEST | [111] |
| Liver          | 2019     | 11.7        | 3                    | 2.4          | 0.39 × 0.39 × 1   | N/A      | Contrast agent: iodinated liposome | [112] |
| Prostate       | 2021     | 7           | 5                    | 3            | 0.3125 × 0.3125 × 1.5 | N/A      | Denoising; acidoCEST | [113] |
|                | 2019     | 11.7        | 3                    | 1.8          | 0.39 × 0.39 × 1   | 1242     | Contrast agent: dextran; dexCEST | [114] |
| Kidney         | 2019     | 9.4         | 4                    | 1.6          | 0.31 × 0.47 × 1   | ~3000    | Respiratory trigger; glucoCEST | [115] |
|                | 2018     | 7           | 6                    | 3.5          | 1.0, 1.5, 2.0     | 254      | Contrast agent; respiration-gated acidoCEST | [116] |
|                | 2017     | 7           | 2                    | 3.0          | 0.5 × 0.5 × 0.5   | 310      | Contrast agent: acidoCEST | [117] |
|                | 2016     | 3           | 5                    | 3            | 0.3125 × 0.3125 × 1.5 | 276      | Contrast agent: acidoCEST | [118] |

For non-APTw imaging, Zijl et al. [35] quantified the hydroxyl proton signal at 1 ppm using MTR\(_{\text{asym}}\) to detect the relative content of glycogen in mouse livers. Zhou et al. [34] found that the intensity of the NOE signal at −1 ppm was also contributed by glycogen (thus namely glycoNOE) and validated this notion in mouse livers after fasting and glucagon injection. Together these studies highlight the potential of liver tumor detection by imaging glycogen using CEST.

GlucoCEST MR was used in a prostate study by Kim et al. [63], who found that the Gaussian hyperglycaemic clamp infusion that is based on the DeFronzo method demon-
strained higher efficiency and stability of glucose delivery as compared to manual determination of glucose infusion rates. Dynamic glucose enhancement (DGE) signal sensitivity was found to be dependent on $T_2$, $B_0$ saturation power, and integration range. Motion correction and $B_0$ field inhomogeneity correction are crucial to avoid mistaking signal changes for a glucose response while field drift is a substantial contributor. However, after $B_0$ field drift correction, no significant glucoCEST signal enhancement was observed in tumor regions of all patients. Thus, glucoCEST at 3 T is not yet practicable in body regions and physical movements and the effects of $B_1$ and $B_0$ made the originally small glucoCEST signal difficult to detect. Nasopharyngeal [102] and pancreatic cancers [106–110] were studied in animal models. CEST was used to detect tumor [108–110] and characterize the tumor tissue dynamically during therapy [102,106,107]. The magnetic strength of the scanner that was used in the studies of the pancreas was still too high for clinical usage. Nevertheless, CEST imaging of non-brain tumors, either with or without a contrast agent, is a promising clinical tool that is useful for tumor diagnosis and prognosis.

Funding: The authors acknowledge funding from National Key R&D Program of China (2020YFC2007300, 2020YFC2007301) and National Natural Science Foundation of China (82071914).

Acknowledgments: The authors would like to express their gratitude to EditSprings (https://www.editsprings.cn/) for the expert linguistic services provided.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Wolff, S.D.; Balaban, R.S. Magnetization transfer contrast (MTC) and tissue water proton relaxation in vivo. Magn. Reson. Med. 1989, 10, 135–144. [CrossRef]
2. Guivel-Scharena, V.; Sinnwell, T.; Wolff, S.; Balaban, R. Detection of Proton Chemical Exchange between Metabolites and Water in Biological Tissues. J. Magn. Reson. 1998, 133, 36–45. [CrossRef] [PubMed]
3. Ward, K.; Aletras, A.; Balaban, R. A New Class of Contrast Agents for MRI Based on Proton Chemical Exchange Dependent Saturation Transfer (CEST). J. Magn. Reson. 2000, 143, 79–87. [CrossRef] [PubMed]
4. Consolino, L.; Anemone, A.; Capozza, M.; Carella, A.; Irrera, P.; Corrado, A.; Dhakan, C.; Bracesco, M.; Longo, D.L. Non-invasive Investigation of Tumor Metabolism and Acidosis by MRI-CEST Imaging. Front. Oncol. 2020, 10, 161. [CrossRef] [PubMed]
5. Chen, Z.; Han, Z.; Liu, G. Repurposing Clinical Agents for Chemical Exchange Saturation Transfer Magnetic Resonance Imaging: Current Status and Future Perspectives. Pharmaceuticals 2020, 14, 11. [CrossRef] [PubMed]
6. Zhou, J.; Heo, H.-Y.; Knutsson, L.; Van Zijl, P.C.; Jiang, S. APT-weighted MRI: Techniques, current neuro applications, and challenging issues. J. Magn. Reson. Imaging 2019, 50, 347–364. [CrossRef] [PubMed]
7. Jones, K.M.; Bs, A.C.P.; Pagel, M.D. Clinical applications of chemical exchange saturation transfer (CEST) MRI. J. Magn. Reson. Imaging 2018, 47, 11–27. [CrossRef] [PubMed]
8. Okuchi, S.; Hamman, A.; Golay, X.; Kim, M.; Thust, S. Endogenous Chemical Exchange Saturation Transfer MRI for the Diagnosis and Therapy Response Assessment of Brain Tumors: A Systematic Review. Radiol. Imaging Cancer 2020, 2, e190036. [CrossRef]
9. Zhou, J.; Wilson, D.A.; Sun, P.Z.; Klaus, J.A.; van Zijl, P.C. Quantitative description of proton exchange processes between water and endogenous agents for WEX, CEST, and APT experiments. Magn. Reson. Med. 2004, 51, 945–952. [CrossRef]
10. Sherry, A.D.; Woods, M. Chemical Exchange Saturation Transfer Contrast Agents for Magnetic Resonance Imaging. Annu. Rev. Biomed. Eng. 2008, 10, 391–411. [CrossRef]
11. Kogan, F.; Harirhan, H.; Reddy, R. Chemical Exchange Saturation Transfer (CEST) Imaging: Description of Technique and Potential Clinical Applications. Curr. Radiol. Rep. 2013, 1, 102–114. [CrossRef]
12. Sun, P.Z.; Wang, E.F.; Cheung, J.S.; Zhang, X.A.; Benner, T.; Sorensen, A.G. Simulation and optimization of pulsed radio frequency irradiation scheme for chemical exchange saturation transfer (CEST) MRI-demonstration of pH-weighted pulsed-amide proton CEST MRI in an animal model of acute cerebral ischemia. Magn. Reson. Med. 2011, 66, 1042–1048. [CrossRef]
13. Grad, J.; Bryant, R.G. Nuclear magnetic cross-relaxation spectroscopy. J. Magn. Reson. 1990, 90, 1–8. [CrossRef]
14. Van Zijl, P.C.; Yadav, N.N. Chemical exchange saturation transfer (CEST): What is in a name and what isn’t? Magn. Reson. Med. 2011, 65, 927–948. [CrossRef] [PubMed]
15. Zhou, I.Y.; Lu, D.; Ji, Y.; Wu, L.; Wang, E.; Cheung, J.S.; Zhang, X.A.; Sun, P.Z. Determination of multipool contributions to endogenous amide proton transfer effects in global ischemia with high spectral resolution in vivo chemical exchange saturation transfer MRI. Magn. Reson. Med. 2019, 81, 645–652. [CrossRef] [PubMed]
16. Wu, Y.; Zhou, I.Y.; Lu, D.; Manderville, E.; Lo, E.H.; Zheng, H.; Sun, P.Z. pH-sensitive amide proton transfer effect dominates the magnetization transfer asymmetry contrast during acute ischemia-quantification of multipool contribution to in vivo CEST MRI. Magn. Reson. Med. 2018, 79, 1602–1608. [CrossRef] [PubMed]
17. Tietze, A.; Blicher, J.; Mikkelson, I.K.; Østergaard, L.; Strother, M.K.; Smith, S.A.; Donahue, M.J. Assessment of ischemic penumbra in patients with hyperacute stroke using amide proton transfer (APT) chemical exchange saturation transfer (CEST) MRI. NMR Biomed. 2014, 27, 163–174. [CrossRef]

18. Zhang, L.; Zhao, Y.; Chen, Y.; Bie, C.; Liang, Y.; He, X.; Song, X. Voxel-wise Optimization of Pseudo Voigt Profile (VOPVP) for Z-spectra fitting in chemical exchange saturation transfer (CEST) MRI. Quant. Imaging Med. Surg. 2019, 9, 1714–1730. [CrossRef] [PubMed]

19. Heo, H.-Y.; Zhang, Y.; Jiang, S.; Lee, D.-H.; Zhou, J. Quantitative assessment of amide proton transfer (APT) and nuclear overhauser enhancement (NOE) imaging with extrapolated semisolid magnetization transfer reference (EMR) signals: II. Comparison of three EMR models and application to human brain glioma at. Magn. Reson. Med. 2016, 75, 1630–1639. [CrossRef]

20. Jin, T.; Wang, P.; Zong, X.; Kim, S.G. MRI imaging of the amide-proton transfer effect and the pH-insensitive nuclear overhauser effect at 9.4 T. Magn. Reson. Med. 2013, 69, 760–770. [CrossRef]

21. Woessner, D.E.; Zhang, S.; Merritt, M.E.; Sherry, A.D. Numerical solution of the Bloch equations provides insights into the optimum design of PARACEST agents for MRI. Magn. Reson. Med. 2005, 53, 790–799. [CrossRef] [PubMed]

22. Zaiss, M.; Xu, J.; Goerke, S.; Khan, I.S.; Singer, R.J.; Gore, J.C.; Kochergin, D.F.; Bachert, P. Inverse Z-spectrum analysis for spillover-, MT-, and T1-corrected steady-state pulsed CEST-MRI-application to pH-weighted MRI of acute stroke. NMR Biomed. 2014, 27, 240–252. [CrossRef]

23. Pavuluri, K.; McMahon, M.T. pH Imaging Using Chemical Exchange Saturation Transfer (CEST) MRI. Isr. J. Chem. 2017, 57, 862–879. [CrossRef]

24. Sun, P.Z.; Wang, Y.; Dai, Z.; Xiao, G.; Wu, R. Quantitative chemical exchange saturation transfer (qCEST) MRI - RF spillover effect-corrected omega plot for simultaneous determination of labile proton fraction ratio and exchange rate. Contrast Media Mol. Imaging 2014, 9, 268–275. [CrossRef]

25. Zhou, J.; Payen, J.-F.A.; Wilson, D.; Traystman, R.J.; Van Zijl, P.C.M. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI. Nat. Med. 2003, 9, 1085–1090. [CrossRef] [PubMed]

26. Zhou, J.; Lal, B.; Wilson, D.A.; Laterra, J.; van Zijl, P.C. Amide proton transfer (APT) contrast for imaging of brain tumors. Magn. Reson. Med. 2003, 50, 1120–1126. [CrossRef]

27. Zhou, J.; Blakeley, J.O.; Hua, J.; Kim, M.; Laterra, J.; Pomper, M.G.; van Zijl, P.C. Practical data acquisition method for human brain tumor amide proton transfer (APT) imaging. Magn. Reson. Med. 2008, 60, 842–849. [CrossRef] [PubMed]

28. Jiang, S.; Eberhart, C.G.; Zhang, Y.; Heo, H.-Y.; Wen, Z.; Blair, L.; Qin, H.; Lim, M.; Quinones-Hinojosa, A.; Weingart, J.D.; et al. Amide proton transfer-weighted magnetic resonance image-guided stereotactic biopsy in patients with newly diagnosed gliomas. Eur. J. Cancer 2017, 83, 9–18. [CrossRef] [PubMed]

29. Jin, T.; Wang, P.; Zong, X.; Kim, S.G. Magnetic resonance imaging of the Amine–Proton EXchange (APEX) dependent contrast. NeuroImage 2012, 59, 1218–1227. [CrossRef]

30. Cai, K.; Haris, M.; Singh, A.; Kogan, E.; Greenberg, J.H.; Hariharan, H.A.; Detre, J.; Reddy, R. Magnetic resonance imaging of glutamate. Nat. Med. 2012, 18, 302–306. [CrossRef]

31. Goldenberg, J.M.; Pagel, M.D. Assessments of tumor metabolism with CEST MRI. NMR Biomed. 2019, 32, e3943. [CrossRef] [PubMed]

32. Cai, K.; Tain, R-W.; Zhou, X.J.; Damen, F.C.; Scotti, A.M.; Hariharan, H.; Poptani, H.; Reddy, R. Creatine CEST MRI for differentiating gliomas with different degrees of aggressiveness. Mol. Imaging Biol. 2017, 19, 225–232. [CrossRef] [PubMed]

33. Dou, W.; Lin, C.-Y.E.; Ding, H.; Shen, Y.; Dou, C.; Qian, L.; Wen, B.; Wu, B. Chemical exchange saturation transfer magnetic resonance imaging and its main and potential applications in pre-clinical and clinical studies. Quant. Imaging Med. Surg. 2019, 9, 1747–1766. [CrossRef]

34. Zhou, Y.; van Zijl, P.C.M.; Xu, X.; Xu, J.; Li, Y.; Chen, L.; Yadav, N.N. Magnetic resonance imaging of glycogen using its magnetic coupling with water. Proc. Natl. Acad. Sci. Nat. Med. 2020, 117, 3144–3149. [CrossRef] [PubMed]

35. van Zijl, P.C.M.; Jones, C.K.; Ren, J.; Malloy, C.R.; Sherry, A.D. MRI detection of glycogen in vivo by using chemical exchange saturation transfer imaging (glycoCEST). Proc. Natl. Acad. Sci. USA 2007, 104, 4359–4364. [CrossRef]

36. Song, X.; Airan, R.D.; Ariffin, D.R.; Bar-Shir, A.; Kadayakkara, D.K.; Liu, G.; Gilad, A.A.; Van Zijl, P.C.M.; McMahon, M.; Bulte, J.W.M. Label-free in vivo molecular imaging of underglycosylated mucin-1 expression in tumour cells. Nat. Commun. 2015, 6, 6719. [CrossRef] [PubMed]

37. Ling, W.; Regatte, R.R.; Navon, G.; Jerschow, A. Assessment of glycosaminoglycan concentration in vivo by chemical exchange-dependent saturation transfer (gagCEST). Proc. Natl. Acad. Sci. USA 2008, 105, 2266–2270. [CrossRef] [PubMed]

38. Slichter, C.P. In Memory of Albert, W. Overhauser (1925–2011). Appl. Magn. Reson. 2012, 43, 3–6. [CrossRef]

39. van Zijl, P.C.; Lam, W.W.; Xu, J.; Knutsson, L.; Stanisic, G. Magnetization Transfer Contrast and Chemical Exchange Saturation Transfer MRI. Features and analysis of the field-dependent saturation spectrum. NeuroImage 2018, 168, 222–241. [CrossRef] [PubMed]

40. Loi, L.; Zimmermann, F.; Goerke, S.; Korzowski, A.; Meisssner, J.-E.; Deike-Hofmann, K.; Stieber, A.; Bachert, P.; Ladd, M.E.; Schlemmer, H.-P.; et al. Relaxation-compensated CEST (chemical exchange saturation transfer) imaging in breast cancer diagnostics at 7T. Eur. J. Radiol. 2020, 129, 109068. [CrossRef]
41. Zhang, S.; Rauch, G.M.; Adrada, B.E.; Boge, M.; Mohamed, R.M.M.; Abdelhafez, A.H.; Son, J.B.; Sun, J.; Elshafeey, N.A.; White, J.B.; et al. Assessment of Early Response to Neoadjuvant Systemic Therapy in Triple-Negative Breast Cancer Using Amide Proton Transfer–weighted Chemical Exchange Saturation Transfer MRI: A Pilot Study. *Radiol. Imaging Cancer* 2021, 3, e200155. [CrossRef] [PubMed]  
42. Meng, N.; Bs, X.W.; Sun, J.; Huang, L.; Wang, Z.; Wang, K.; Wang, J.; Ms, D.H.; Wang, M. Comparative Study of Amide Proton Transfer-Weighted Imaging and Intravoxel Incoherent Motion Imaging in Breast Cancer Diagnosis and Evaluation. *J. Magn. Reson. Imaging* 2020, 52, 1175–1186. [CrossRef] [PubMed]  
43. Crescenzi, R.; Donahue, P.M.C.; Mahany, H.; Lants, S.K.; Donahue, M.J. CEST MRI quantification procedures for breast cancer treatment-related lymphedema therapy evaluation. *Magn. Reson. Med.* 2020, 83, 1760–1773. [CrossRef] [PubMed]  
44. Zaric, O.; Farr, A.; Rodriguez, E.P.; Mlynarik, V.; Bogner, W.; Gruber, S.; Asseryanis, E.; Singer, C.F.; Trattnig, S. 7T CEST MRI: A potential imaging tool for the assessment of tumor grade and cell proliferation in breast cancer. *Magn. Reson. Imaging* 2019, 59, 77–87. [CrossRef]  
45. Zhang, S.; Seiler, S.; Wang, X.; Madhuranthakam, A.J.; Keupp, J.; Knippa, E.E.; Lenkineski, R.E.; Vinogradov, E. CEST-Dixon for imaging of the human breast lesion characterization at 3 T: A preliminary study. *Magn. Reson. Med.* 2018, 80, 895–903. [CrossRef] [PubMed]  
46. Krikken, E.; Khlebnikov, V.; Zaiss, M.; Jibodh, R.A.; van Diest, P.J.; Luijten, P.R.; Klomp, D.W.J.; van Laarhoven, H.W.M.; Wijnen, J.P. Amide chemical exchange saturation transfer at 7 T: A possible biomarker for detecting early response to neoadjuvant chemotherapy in breast cancer patients. *Breast Cancer Res.* 2018, 20, 1–9. [CrossRef]  
47. Donahue, M.J.; Donahue, P.C.; Rane, S.; Thompson, C.R.; Strother, M.K.; Scott, A.O.; Smith, S.A. Assessment of lymphatic impairment and interstitial protein accumulation in patients with breast cancer treatment-related lymphedema using CEST MRI. *Magn. Reson. Med.* 2016, 75, 345–355. [CrossRef] [PubMed]  
48. Dula, A.N.; Dewey, B.E.; Arlinghaus, L.R.; Williams, J.M.; Klomp, D.; Yankeelov, T.E.; Smith, S. Optimization of 7-T Chemical Exchange Saturation Transfer Parameters for Validation of Glycosaminoglycan and Amide Proton Transfer of Fibroglanular Breast Tissue. *Radiology* 2015, 275, 255–261. [CrossRef] [PubMed]  
49. Klomp, D.W.; Dula, A.N.; Arlinghaus, L.R.; Italiaander, M.; Dortch, R.D.; Zu, Z.; Williams, J.M.; Gochberg, D.F.; Luijten, P.R.; Gore, J.C.; et al. Amide proton transfer imaging of the human breast at 7T: Development and reproducibility. *NMR Biomed.* 2013, 26, 1271–1277. [CrossRef] [PubMed]  
50. Dula, A.N.; Arlinghaus, L.; Dortch, R.; Dewey, B.E.; Whisenant, J.G.; Ayers, G.D.; Yankeelov, T.; Smith, S.A. Amide proton transfer imaging of the breast at 3 T: Establishing reproducibility and possible feasibility assessing chemotherapy response. *Magn. Reson. Med.* 2013, 70, 216–224. [CrossRef]  
51. Schmitt, B.; Zamecnik, P.; Zaiß, M.; Rerich, E.; Schuster, L.; Bachert, P.; Schlemmer, H.-P. A New Contrast in MR Mammography by Means of Chemical Exchange Saturation Transfer (CEST) Imaging at 3 Tesla: Preliminary Results. *RöFo Fortschr. Geb. Röntgenstrahl. Bildgeb. Verfahr.* 2011, 183, 1030–1036. [CrossRef]  
52. Meng, N.; Wang, J.; Sun, J.; Liu, W.; Wang, X.; Yan, M.; Dwivedi, A.; Zheng, D.; Wang, K.; Han, D. Using amide proton transfer to identify cervical squamous carcinoma/adenocarcinoma and evaluate its differentiation grade. *Magn. Reson. Imaging* 2019, 61, 9–15. [CrossRef]  
53. Li, B.; Sun, H.; Zhang, S.; Wang, X.; Guo, Q. The utility of APT and IVIM in the diagnosis and differentiation of squamous cell carcinoma of the cervix: A pilot study. *Magn. Reson. Imaging* 2019, 63, 105–113. [CrossRef] [PubMed]  
54. He, Y.L.; Li, Y.; Lin, C.Y.; Qi, Y.F.; Wang, X.; Zhou, H.L.; Yang, J.J.; Xiang, Y.; Xue, H.D.; Jin, Z.Y. Three-dimensional turbo-spin-echo amide proton transfer-weighted mri for cervical cancer: A preliminary study. *J. Magn. Reson. Imaging* 2019, 50, 1318–1325. [CrossRef] [PubMed]  
55. Li, B.; Sun, H.; Zhang, S.; Wang, X.; Guo, Q. Amide proton transfer imaging to evaluate the grading of squamous cell carcinoma of the cervix: A comparative study using 18F FDG PET. *J. Magn. Reson. Imaging* 2019, 50, 261–268. [CrossRef] [PubMed]  
56. Ochiai, R.; Mukuda, N.; Yunaga, H.; Kitao, S.; Okuda, K.; Sato, S.; Oishi, T.; Miyoshi, M.; Nozaki, A.; Fujii, S. Amide proton transfer imaging in differentiation of type II and type I endometrial carcinoma: A pilot study. *Jpn. J. Radiol.* 2021, 1–8. [CrossRef]  
57. Meng, N.; Fang, T.; Feng, P.; Huang, Z.; Sun, J.; Wang, X.; Shang, J.; Wang, K.; Han, D.; Wang, M. Amide proton transfer-weighted imaging and multiple models diffusion-weighted imaging facilitates preoperative risk stratification of early-stage endometrial carcinoma. *J. Magn. Reson. Imaging* 2021, 54, 1200–1211. [CrossRef] [PubMed]  
58. Li, Y.; Lin, C.Y.; Qi, Y.F.; Wang, X.; Chen, B.; Zhou, H.L.; Ren, J.; Yang, J.J.; Xiang, Y.; He, Y.L.; et al. Three-dimensional turbo-spin-echo amide proton transfer-weighted and intravoxel incoherent motion MR imaging for type I endometrial carcinoma: Correlation with Ki-67 proliferation status. *Magn. Reson. Imaging* 2021, 78, 18–24. [CrossRef] [PubMed]  
59. Zhang, S.; Sun, H.; Li, B.; Wang, X.; Pan, S.; Guo, Q. Variation of amide proton transfer signal intensity and apparent diffusion coefficient values among the menstrual cycle in the normal uterus: A preliminary study. *Magn. Reson. Imaging* 2019, 63, 21–28. [CrossRef]  
60. Takayama, Y.; Nishie, A.; Togao, O.; Asayama, Y.; Ishigami, K.; Ushijima, Y.; Okamoto, D.; Fujita, N.; Sonoda, K.; Hida, T.; et al. Amide proton transfer MR imaging of endometrioid endometrial adenocarcinoma: Association with histologic grade. *Radiology* 2018, 286, 929–937. [CrossRef]  
61. Yin, H.; Wang, D.; Yan, R.; Jin, X.; Hu, Y.; Zhai, Z.; Duan, J.; Zhang, J.; Wang, K.; Han, D. Comparison of Diffusion Kurtosis Imaging and Amide Proton Transfer Imaging in the Diagnosis and Risk Assessment of Prostate Cancer. *Front. Oncol.* 2021, 11, 10. [CrossRef]
62. Evans, V.S.; Torrealdea, F.; Rega, M.; Appayya, M.B.; Latifoltojar, A.; Sidhu, H.; Kim, M.; Kujawa, A.; Punwani, S.; Golay, X.; et al. Optimization and repeatability of multipool chemical exchange saturation transfer MRI of the prostate at 3.0 T. J. Magn. Reson. Imaging 2019, 50, 1238–1250. [CrossRef] [PubMed]

63. Kim, M.; Torrealdea, F.; Adeleke, S.; Rega, M.; Evans, V.; Beeston, T.; Soteriou, K.; Thust, S.; Kujawa, A.; Okuchi, S.; et al. Challenges in glutoCEST MR body imaging at 3 Tesla. Quant. Imaging Med. Surg. 2019, 9, 1628–1640. [CrossRef]

64. Takayama, Y.; Nishie, A.; Sugimoto, M.; Togao, O.; Asayama, Y.; Ishigami, K.; Ushijima, Y.; Okamoto, D.; Fujita, N.; Yokomizo, A.; et al. Amide proton transfer (APT) magnetic resonance imaging of prostate cancer: Comparison with Gleason scores. Magna Magn. Reson. Mater. Phys. Biol. Med. 2016, 29, 671–679. [CrossRef]

65. Jia, G.; Abaza, R.; Williams, J.D.; Zynger, D.L.; Zhou, J.; Shah, Z.; Patel, M.; Sammet, S.; Wei, L.; Bahnsen, R.R.; et al. Amide proton transfer MR imaging of prostate cancer: A preliminary study. J. Magn. Reson. Imaging 2011, 33, 647–654. [CrossRef]

66. Jones, K.M.; Randtke, E.A.; Yoshimaru, C.M.; Howison, C.M.; Chalasani, P.; Klein, R.R.; Chambers, S.K.; Kuo, P.H.; Pagel, M.D. Clinical Translation of Tumor Acidosis Measurements with AcidoCEST MRI. Mol. Imaging Biol. 2017, 19, 617–625. [CrossRef]

67. Chen, W.; Mao, L.; Li, L.; Wei, Q.; Hu, S.; Ye, Y.; Feng, J.; Liu, B.; Liu, X. Predicting Treatment Response of Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Using Amide Proton Transfer MRI Combined With Diffusion-Weighted Imaging. Front. Oncol. 2021, 11, 698427. [CrossRef] [PubMed]

68. Chen, W.; Li, L.; Yan, Z.; Hu, S.; Feng, J.; Liu, B.; Liu, X. Comparative analysis of amide proton transfer MRI land diffusion-weighted imaging in assessing p53 and Ki-67 expression of rectal adenocarcinoma. J. Magn. Reson. Imaging 2020, 52, 1487–1496. [CrossRef] [PubMed]

69. Chen, W.; Li, L.; Yan, Z.; Hu, S.; Feng, J.; Liu, B.; Liu, X. Three-dimension amide proton transfer MRI of rectal adenocarcinoma: Correlation with pathologic prognostic factors and comparison with diffusion kurtosis imaging. Eur. Radiol. 2021, 31, 3286–3296. [CrossRef]

70. Nishie, A.; Asayama, Y.; Ishigami, K.; Ushijima, Y.; Takayama, Y.; Okamoto, D.; Fujita, N.; Tsurumaru, D.; Togao, O.; Sagiya, K.; et al. Amide proton transfer imaging to predict tumor response to neoadjuvant chemotherpay in locally advanced rectal cancer. J. Gastroenterol. Hepatol. 2019, 34, 140–146. [CrossRef] [PubMed]

71. Nishie, A.; Takayama, Y.; Asayama, Y.; Ishigami, K.; Ushijima, Y.; Okamoto, D.; Fujita, N.; Tsurumaru, D.; Togao, O.; Manabe, T.; et al. Amide proton transfer imaging can predict tumor grade in rectal cancer. Magn. Reson. Imaging 2018, 51, 96–103. [CrossRef]

72. Tang, Y.; Xiao, G.; Shen, Z.; Zhuang, C.; Xie, Y.; Zhang, X.; Yang, Z.; Guan, J.; Shen, Y.; Chen, Y.; et al. Noninvasive Detection of Extracellular pH in Human Benign and Malignant Liver Tumors Using CEST MRI. Front. Oncol. 2020, 10, 578985. [CrossRef]

73. Lin, Y.; Luo, X.; Yu, L.; Zhang, Y.; Zhou, J.; Jiang, Y.; Zhang, C.; Zhang, J.; Li, C.; Chen, M. Amide proton transfer-weighted MRI for predicting histological grade of hepatocellular carcinoma: Comparison with diffusion-weighted imaging. Quant. Imaging Med. Surg. 2019, 9, 1641–1651. [CrossRef]

74. Chen, Y.; Wang, X.; Su, T.; Xu, Z.; Wang, Y.; Zhang, Z.; Xue, H.; Zhuo, Z.; Zhu, Y.; Jin, Z.; et al. Feasibility evaluation of amide proton transfer-weighted imaging in the parotid glands: A strategy to recognize artifacts and measure APT value. Quant. Imaging Med. Surg. 2021, 11, 2279–2291. [CrossRef]

75. Takumi, K.; Nagano, H.; Kikuno, H.; Kumagae, Y.; Fukukura, Y.; Yoshiura, T. Differentiating malignant from benign salivary gland lesions: A multiparametric non-contrast MRI imaging approach. Sci. Rep. 2021, 11, 1–9. [CrossRef]

76. Bae, Y.J.; Choi, B.S.; Jeong, W.-J.; Jung, Y.H.; Park, J.H.; Sunwoo, L.; Jung, C.; Kim, J.H. Amide Proton Transfer-weighted MRI in the Diagnosis of Major Salivary Gland Tumors. Sci. Rep. 2019, 9, 8349. [CrossRef] [PubMed]

77. Yu, L.; Li, C.M.; Luo, X.J.; Zhou, J.Y.; Zhang, C.; Chen, M. Differentiation of malignant and benign head and neck tumors with amide proton transfer-weighted MR imaging. Mol. Imaging Biol. 2019, 21, 348–355. [CrossRef]

78. Yuan, J.; Chen, S.; King, A.; Zhou, J.; Bhatia, K.S.; Zhang, Q.; Yeung, D.K.W.; Wei, J.; Mok, G.S.P.; Wang, Y.-X. Amide proton transfer-weighted imaging of the head and neck at 3 T: A feasibility study on healthy human subjects and patients with head and neck cancer. NMR Biomed. 2014, 27, 1239–1247. [CrossRef] [PubMed]

79. Jones, K.; Stuehm, C.; Hsu, C.; Kuo, P.; Pagel, M.; Randtke, E. Imaging Lung Cancer by Using Chemical Exchange Saturation Transfer MRI With Retrospective Respiration Gating. Tomography 2017, 3, 201–210. [CrossRef]

80. Ohno, Y.; Kishida, Y.; Seki, S.; Yui, M.; Miyazaki, M.; Koyama, H.; Yoshikawa, T. Amide proton transfer-weighted imaging to differentiate malignant from benign pulmonary lesions: Comparison with diffusion-weighted imaging and FDG-PET/CT. J. Magn. Reson. Imaging 2018, 47, 1013–1021. [CrossRef] [PubMed]

81. Ohno, Y.; Yui, M.; Koyama, H.; Yoshikawa, T.; Seki, S.; Ueno, Y.; Miyazaki, M.; Ouyang, C.; Sugimura, K. Chemical Exchange Saturation Transfer MR Imaging: Preliminary Results for Differentiation of Malignant and Benign Thoracic Lesions. Radiology 2016, 279, 578–589. [CrossRef] [PubMed]

82. Kim, M.; Gillen, J.; Landman, B.A.; Zhou, J.; van Zijl, P.C. Water saturation shift referencing (WASSR) for chemical exchange saturation transfer (CEST) experiments. Magn. Reson. Med. 2009, 61, 1441–1450. [CrossRef]

83. Insko, E.; Bolinger, L. Mapping of the Radiofrequency Field. J. Magn. Reson. Ser. A 1993, 103, 82–85. [CrossRef]

84. Cunningham, C.H.; Pauly, J.M.; Nayak, K.S. Saturated double-angle method for rapid B-1 plus mapping. Magn. Reson. Med. 2006, 55, 1326–1333. [CrossRef] [PubMed]
111. Sinharay, S.; Howison, C.M.; Baker, A.F.; Pagel, M.D. Detecting in vivo urokinase plasminogen activator activity with a catalyCEST MRI contrast agent. NMR Biomed. 2017, 30, e3721.

112. Chen, Z.; Li, Y.; Airan, R.; Han, Z.; Xu, J.; Chan, K.W.; Xu, Y.; Bulte, J.W.M.; Van Zijl, P.C.M.; McMahon, M.T.; et al. CT and CEST MRI bimodal imaging of the intratumoral distribution of iodinated liposomes. Quant. Imaging Med. Surg. 2019, 9, 1579–1591. [CrossRef] [PubMed]

113. Romdhane, F.; Villano, D.; Irrera, P.; Consolino, L.; Longo, D.L. Evaluation of a similarity anisotropic diffusion denoising approach for improving in vivo CEST-MRI tumor pH imaging. Magn. Reson. Med. 2021, 85, 3479–3496. [CrossRef] [PubMed]

114. Chen, H.; Liu, D.; Li, Y.; Xu, X.; Xu, J.; Yadav, N.N.; Zhou, S.; Van Zijl, P.C.M.; Liu, G. CEST MRI monitoring of tumor response to vascular disrupting therapy using high molecular weight dextrans. Magn. Reson. Med. 2019, 82, 1471–1479. [CrossRef]

115. Han, Z.; Liu, G. Sugar-based biopolymers as novel imaging agents for molecular magnetic resonance imaging. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2019, 11, e1551. [CrossRef]

116. Lindeman, L.R.; Randtke, E.A.; High, R.A.; Jones, K.M.; Howison, C.M.; Pagel, M.D. A comparison of exogenous and endogenous CEST MRI methods for evaluating in vivo pH. Magn. Reson. Med. 2018, 79, 2766–2772. [CrossRef]

117. Randtke, E.A.; Granados, J.; Howison, C.M.; Pagel, M.D.; Cárdenas-Rodríguez, J. Multislice CEST MRI improves the spatial assessment of tumor pH. Magn. Reson. Med. 2017, 78, 97–106. [CrossRef]

118. Longo, D.; Bartoli, A.; Consolino, L.; Bardini, P.; Arena, F.; Schwaiger, M.; Aime, S. In Vivo Imaging of Tumor Metabolism and Acidosis by Combining PET and MRI-CEST pH Imaging. Cancer Res. 2016, 76, 6463–6470. [CrossRef] [PubMed]

119. Sinharay, S.; Randtke, E.A.; Howison, C.M.; Ignatenko, N.A.; Pagel, M.D. Detection of Enzyme Activity and Inhibition during Studies in Solution, In Vitro and In Vivo with CatalyCEST MRI. Mol. Imaging Biol. 2018, 20, 240–248.